Juxtaglomerular cell tumor in a young male presenting with new onset congestive heart failure
Publication date: Available online 5 April 2020Source: Urology Case ReportsAuthor(s): Arvind Krishnan, Jeffy Jacob, Trushar Patel
ConclusionPatients newly diagnosed with ATTRv amyloidosis have substantial healthcare utilization and costs in the first year, primarily the initial months, post-diagnosis. Further research should examine later costs associated with disease progression and end-of-life care.
This article aims to review the key connections in the epidemiology and etiopathophysiology of type 2 diabetes and heart failure
The objective of this study is to assess the impact of ventricular arrhythmias on in-hospital mortality and the use of mechanical circulatory support in patients with myocarditis. Pediatric patients (age 0 –18 years) admitted with myocarditis were identified from the National Inpatient Sample dataset for the years 2002–2015. A total of 12,489 patients with myocarditis were identified. Of them, 1627 patients were with ventricular arrhythmias and 10,862 patients without ventricular arrhythmias. Mor tality was higher in those with ventricular arrhythmias (19.5% vs. 2.8%, OR = 8.47; 95% CI 7.16–10.04;p
Conclusion: The CareWell program resulted in improvements in the use of health services, strengthening the role of PC as the cornerstone of care provision for complex patients with multimorbidity. Published on 2020-05-22 11:47:30
Authors: Sun X, Chen G, Xie Y, Jiang D, Han J, Chen F, Song Y Abstract Context: Therapeutic doxorubicin administration is restricted as this anticancer drug may be cardiotoxic. The traditional Chinese medicine qiliqiangxin has been approved for clinical treatment of chronic heart failure.Objective: To explore the protective effects and molecular mechanisms of qiliqiangxin on doxorubicin-induced congestive heart failure (CHF) in rats.Materials and methods: A CHF rat model was established via intraperitoneal DOX injections (2.5 mg/kg/week) for 6 weeks. The rats were randomly assigned to control, CHF, CHF&thins...
AbstractBackgroundThe high surgical risk in redo cardiac surgery is largely attributed to adhesions around the epicardium and the great vessels. BAX602 is an adhesion prevention reagent composed of two synthetic polyethylene glycols. Spraying BAX602 over the epicardium and the great vessels reportedly contributes to adhesion prevention after pediatric cardiac surgery. The present study aims to evaluate the safety and effectiveness of BAX602 spray in patients undergoing extracorporeal ventricular assist device implantation surgery to treat refractory congestive heart failure.Methods and DesignThis investigator-initiated, mu...
Authors: Lehto HR, Pietilä A, Niiranen TJ, Lommi J, Salomaa V Abstract Aims: To compare diabetic patients with coronary heart disease (CHD) needing revascularization to corresponding non-diabetic patients in terms of revascularization methods, comorbidities and urgency of procedure. We also examined the impact of patient characteristics and comorbidities on the revascularization method.Methods: We identified all diabetic (n = 33,018) and non-diabetic (n = 106,224) patients with first-ever, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) from electr...
Publication date: Available online 1 May 2020Source: Journal of Taibah University Medical SciencesAuthor(s): Eman M. Alfadhli
An 84-year old presented to the emergency room with 4 days of left lower back discomfort that is noted as dull and aching, intermittent, and rated as 6/10 in severity. He has had an endovascular aortic aneurysm repair 16 years previous but was told no further surveillance was necessary, and as such, has not had any imaging in over 12 years. He had multiple medical comorbidities including advanced COPD on 3L nasal cannula and congestive heart failure, and sleeps sitting up in a chair. He had a 58-pack year history of tobacco use and is retired from the automobile industry.
Condition: Congestive Heart Failure Interventions: Device: EKO; Device: BodyPort; Other: Noom; Other: Conversa Sponsors: Yale University; Boehringer Ingelheim; Medullan Not yet recruiting